aibioMapLight IPO closes; additional-share option brings gross proceeds to $288.4 million
MapLight Therapeutics closed its initial public offering at $17.00 a share, and the underwriters exercised their option for more shares in full. Its lead drug has no Phase 2 results yet.
Key facts
- Companies
- MapLight Therapeutics, Inc. (NASDAQ: MPLT), Goldman Sachs Group Inc (NYSE: GS)
- News type
- Financings
- Primary source
- MPLT 8-K
MapLight Therapeutics (Nasdaq: MPLT) closed the initial public offering of 14,750,000 shares of common stock on October 28, 2025, at $17.00 a share, according to a Form 8-K filed with the Securities and Exchange Commission. The underwriters exercised their 30-day option in full the same day for 2,212,500 more shares, and those shares closed on October 29, 2025.
The company also sold stock to existing stockholders in a concurrent private placement that closed alongside the IPO. Affiliates of Goldman Sachs & Co. LLC bought the shares at the IPO price. The 8-K gives 467,707 shares for that placement, while the final prospectus dated October 26, 2025 gives 476,707. The filings do not explain the difference. The 8-K says the placement shares were not registered and were sold to institutional accredited investors without general solicitation.
The offering terms
According to the prospectus, the 14,750,000 base shares carried a total offering price of $250,750,000. Underwriting discounts and commissions were $1.19 a share, or $17,552,500, leaving proceeds before expenses of $15.81 a share, or $233,197,500. The 8-K says gross proceeds from the IPO and the private placement, before underwriting discounts, placement agent fees and offering expenses, were $296.3 million.
The company's amended and restated certificate of incorporation and bylaws took effect at the closing, as the board and stockholders had approved before the IPO. The prospectus says the company will offer voting common stock to the public, while a separate non-voting common stock class will not be listed. The company says it may qualify as a "controlled company" under Nasdaq rules but does not intend to use the exemptions that status allows. For public buyers, that means the listed shares are voting shares in a company where a controlled-company structure is possible.
Banks and placement agents
Morgan Stanley & Co. LLC, Jefferies LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated signed the underwriting agreement on October 26, 2025, as representatives of the several underwriters. The same four firms acted as placement agents for the concurrent private placement and received a placement agent fee of 7.0% of the total purchase price of those shares. The 8-K names no counsel.
The prospectus also says accounts advised by T. Rowe Price Investment Management, Inc. indicated interest in buying up to $40 million of shares in the IPO at the IPO price. The prospectus calls those indications non-binding, and says the shares TRPIM would buy will not be subject to a lock-up agreement with the underwriters. The indication is not a commitment, so the offering did not depend on it.
The drug and what is still ahead
MapLight describes itself as a clinical-stage biopharmaceutical company focused on central nervous system disorders. Its lead candidate, ML-007C-MA, pairs ML-007, an M1 and M4 muscarinic agonist, with a peripherally acting anticholinergic. The company says that pairing is meant to limit peripheral cholinergic side effects. The drug is being developed first for schizophrenia and Alzheimer's disease psychosis.
The prospectus says ML-007 alone, given together with the anticholinergic, or formulated with it, has been tested in four Phase 1 trials with a total of 270 healthy participants and more than 1,500 doses. The company says it "has demonstrated the potential to be a well-tolerated treatment option." Those are early studies in healthy volunteers, and the cited filings report no Phase 2 results. The two Phase 2 trials are ZEPHYR, in schizophrenia, with topline results expected in the second half of 2026, and VISTA, in Alzheimer's disease psychosis, with topline results expected in the second half of 2027.
The prospectus calls atypical antipsychotics the current standard of care for schizophrenia. The company's pitch rests on beating that standard on symptoms and side effects, and the trials that would test that claim have not reported.
This story does not report the company's cash, net loss or runway at the time of the IPO. This story therefore cannot set the offering proceeds against what the company spends.